4.7 Article

Primary resistance to integrase inhibitors in Shenzhen

Related references

Note: Only part of the references are listed.
Article Public, Environmental & Occupational Health

Use of HIV Post-Exposure Prophylaxis Among Men Who Have Sex With Men in Shenzhen, China: A Serial Cross-Sectional Study

Yao Wang et al.

Summary: This study examined the use of HIV postexposure prophylaxis (PEP) and factors associated with PEP in Men who have sex with men (MSM) in China. The findings showed an increasing trend in PEP use over the years. Factors associated with PEP use included shorter residence in the study area, heterosexual intercourse, seeking sexual partners in MSM venues, multiple sexual partners, and interest in initiating Pre-exposure prophylaxis (PrEP). The implementation of PEP programs should focus on high-risk groups and their risky behaviors.

AIDS AND BEHAVIOR (2022)

Review Infectious Diseases

HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance

Nokuzola Mbhele et al.

Summary: Antiretroviral therapy is crucial in controlling the HIV epidemic, with integrase strand transfer inhibitors (INSTIs) becoming more common. INSTIs have a higher genetic barrier to resistance, with DTG showing even higher resistance barriers and CAB being used as the first long-acting agent in HIV-1 treatment.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)

Article Infectious Diseases

Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020)

Zhaojie Yang et al.

Summary: This study investigated the prevalence of acquired and transmitted INSTI-associated resistance of HIV-1 strains in Henan Province, China. Results showed that INSTI resistance was observed in INSTI-treated patients, with low prevalence in ART-naive patients. Baseline INSTI resistance testing should be considered as prescription of INSTI-based regimens is expected to increase in the future.

INFECTION (2021)

Article Infectious Diseases

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance

Philip L. Tzou et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

Review Immunology

Long-acting injectable cabotegravir for the prevention of HIV infection

Meredith E. Clement et al.

CURRENT OPINION IN HIV AND AIDS (2020)

Review Medicine, General & Internal

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2020 Recommendations of the International Antiviral Society-USA Panel

Michael S. Saag et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Review Virology

Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations

Charlotte Charpentier et al.

VIRUSES-BASEL (2018)